|
1
|
Sun X, Yang S, He Z, Wang L and He J:
Integrated network pharmacology and transcriptomics to explore the
mechanism of compound Dihuang granule (CDG) protects dopaminergic
neurons by regulating the Nrf2/HMOX1 pathway in the
6-OHDA/MPP+-induced of Parkinson's disease. Chin Med.
19:1702024. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lim SY, Tan AH, Ahmad-Annuar A, Klein C,
Tan LCS, Rosales RL, Bhidayasiri R, Wu YR, Shang HF, Evans AH, et
al: Parkinson's disease in the western pacific region. Lancet
Neurol. 18:865–879. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhu J, Cui Y, Zhang J, Yan R, Su D, Zhao
D, Wang A and Feng T: Temporal trends in the prevalence of
Parkinson's disease from 1980 to 2023: A systematic review and
meta-analysis. Lancet Healthy Longev. 5:e464–e479. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Postuma RB, Poewe W, Litvan I, Lewis S,
Lang AE, Halliday G, Goetz CG, Chan P, Slow E, Seppi K, et al:
Validation of the MDS clinical diagnostic criteria for Parkinson's
disease. Mov Disord. 33:1601–1608. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Postuma RB, Berg D, Stern M, Poewe W,
Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, et al:
MDS clinical diagnostic criteria for Parkinson's disease. Mov
Disord. 30:1591–1601. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Marini K, Seppi K, Tschiderer L, Kiechl S,
Stockner H, Willeit P, Willeit J, Djamshidian A, Rungger G, Poewe W
and Mahlknecht P: Application of the updated movement disorder
society criteria for prodromal Parkinson's disease to a
population-based 10-year study. Mov Disord. 36:1464–1466. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ben-Shlomo Y, Darweesh S, Llibre-Guerra J,
Marras C, San Luciano M and Tanner C: The epidemiology of
Parkinson's disease. Lancet. 403:283–292. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang Y, Yue H, Kuang H and Wang J: SDMFF:
Spatial-temporal dual-pathway network with multi-scale feature
fusion for Parkinson's disease diagnosis. Tang J, Lai X, Cai Z,
Peng W and Wei Y: Bioinformatics Research and Applications. ISBRA
2025. Lecture Notes in Computer Science. Vol. 15756. Springer;
Singapore: pp. 98–109. 2026
|
|
9
|
Shi D, Wu S, Zhuang C, Mao Y, Wang Q, Zhai
H, Zhao N, Yan G and Wu R: Multimodal data fusion reveals
functional and neurochemical correlates of Parkinson's disease.
Neurobiol Dis. 197:1065272024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tarakad A: Motor features of Parkinson's
disease. Neurol Clin. 43:279–289. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gu Y, Zhang J, Zhao X, Nie W, Xu X, Liu M
and Zhang X: Olfactory dysfunction and its related molecular
mechanisms in Parkinson's disease. Neural Regen Res. 19:583–590.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mammen JR, Adams JL, Mangrum R, Xiao Y,
Barbosa W, Tyo M, Redmond C, Carter C, Cifelli K, Cifelli R, et al:
Systematic review and consensus conceptual model of meaningful
symptoms and functional impacts in early Parkinson's disease. NPJ
Parkinsons Dis. 11:652025. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Passaretti M, Veréb D, Mijalkov M, Chang
YW, Zhao H, Zufiria-Gerbolés B, Sun J, Volpe G, Rivera N, Bologna M
and Pereira JB: Clinical progression and genetic pathways in
body-first and brain-first Parkinson's disease. Mol Neurodegener.
20:742025. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kouli A, Camacho M, Allinson K and
Williams-Gray CH: Neuroinflammation and protein pathology in
Parkinson's disease dementia. Acta Neuropathol Commun. 8:2112020.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Andica C and Kamagata K: Neural plasticity
in Parkinson's disease: A neuroimaging perspective. Neural Regen
Res. 19:1203–1205. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Iarkov A, Barreto GE, Grizzell JA and
Echeverria V: Strategies for the treatment of Parkinson's disease:
Beyond dopamine. Front Aging Neurosci. 12:42020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vidyadhara DJ, Lee JE and Chandra SS: Role
of the endolysosomal system in Parkinson's disease. J Neurochem.
150:487–506. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim S, Kwon SH, Kam TI, Panicker N,
Karuppagounder SS, Lee S, Lee JH, Kim WR, Kook M, Foss CA, et al:
Transneuronal propagation of pathologic α-synuclein from the gut to
the brain models Parkinson's disease. Neuron. 103:627–641.e7. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tremlett H, Bauer KC, Appel-Cresswell S,
Finlay BB and Waubant E: The gut microbiome in human neurological
disease: A review. Ann Neurol. 81:369–382. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mayer EA, Tillisch K and Gupta A:
Gut/brain axis and the microbiota. J Clin Invest. 125:926–938.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ran Z, Mu BR, Wang DM, Huang X, Ma QH and
Lu MH: Parkinson's Disease and the microbiota-gut-brain axis:
Metabolites, mechanisms, and innovative therapeutic strategies
targeting the gut microbiota. Mol Neurobiol. 62:5273–5296. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ratajczyk K, Kaczorowska E, Wyka K,
Tarasiuk-Zawadzka A, Fichna J and Gajos A: Gut-brain signaling in
Parkinson's disease: A narrative review. Int J Mol Sci.
27:35312026. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lynch SV and Pedersen O: The human
intestinal microbiome in health and disease. N Engl J Med.
375:2369–2379. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zuo T: Pushing the frontier of gut
microbiome health cross-kingdom and cross-organ. Nat Rev
Gastroenterol Hepatol. 23:112–114. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Reddy LB and Saier MH Jr: Microbiome:
Friend or friendly foe. Microb Physiol. 35:102–114. 2025.
View Article : Google Scholar
|
|
26
|
Jyoti Dey P: Mechanisms and implications
of the gut microbial modulation of intestinal metabolic processes.
NPJ Metab Health Dis. 3:242025. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu S, Gao J, Zhu M, Liu K and Zhang HL:
Gut microbiota and dysbiosis in Alzheimer's disease: Implications
for pathogenesis and treatment. Mol Neurobiol. 57:5026–5043. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ma YY, Li X, Yu JT and Wang YJ:
Therapeutics for neurodegenerative diseases by targeting the gut
microbiome: From bench to bedside. Transl Neurodegener. 13:122024.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tillisch K and Labus JS: Advances in
imaging the brain-gut axis: Functional gastrointestinal disorders.
Gastroenterology. 140:407–411.e1. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang X, Zhang W, Wang H, Zhao Y, Wang P,
Wang R, Sun Y, Ren F and Li Y: Dietary modulation of the enteric
nervous system: From molecular mechanisms to therapeutic
applications. Nutrients. 17:35192025. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Furness JB, Marklund U, Czapla BJ,
Bornstein JC and Han MN: Functional characterization and
classification of enteric neurons, and regional differences in
neural control of digestive functions. Auton Neurosci.
265:1034122026. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Furness JB: The enteric nervous system and
neurogastroenterology. Nat Rev Gastroenterol Hepatol. 9:286–294.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mandal R, Paul T and Debnath R:
Understanding the gut-brain axis with methodological challenges and
transitional barriers in neurophysiology. Int J Nutr Pharmacol
Neurol Dis. 16:312026. View Article : Google Scholar
|
|
34
|
Browning KN, Travagli RA and Pellegrini C:
Central control of gastrointestinal functions in health and
disease. Physiol Rev. 106:971–1020. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Morais LH, Schreiber HL IV and Mazmanian
SK: The gut microbiota-brain axis in behaviour and brain disorders.
Nat Rev Microbiol. 19:241–255. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ashique S, Mohanto S, Ahmed MG, Mishra N,
Garg A, Chellappan DK, Omara T, Iqbal S and Kahwa I: RETRACTED:
Gut-brain axis: A cutting-edge approach to target neurological
disorders and potential synbiotic application. Heliyon.
10:e340922024. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhou Y, Chen Y, He H, Peng M, Zeng M and
Sun H: The role of the indoles in microbiota-gut-brain axis and
potential therapeutic targets: A focus on human neurological and
neuropsychiatric diseases. Neuropharmacology. 239:1096902023.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dong F and Perdew GH: The aryl hydrocarbon
receptor as a mediator of host-microbiota interplay. Gut Microbes.
12:18598122020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Scott SA, Fu J and Chang PV: Microbial
tryptophan metabolites regulate gut barrier function via the aryl
hydrocarbon receptor. Proc Natl Acad Sci USA. 117:19376–19387.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wei GZ, Martin KA, Xing PY, Agrawal R,
Whiley L, Wood TK, Hejndorf S, Ng YZ, Low JZY, Rossant J, et al:
Tryptophan-metabolizing gut microbes regulate adult neurogenesis
via the aryl hydrocarbon receptor. Proc Natl Acad Sci USA.
118:e20210911182021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zulfiqar M, Singh V, Steinbeck C and
Sorokina M: Review on computer-assisted biosynthetic capacities
elucidation to assess metabolic interactions and communication
within microbial communities. Crit Rev Microbiol. 50:1053–1092.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ji Q, Jiang X, Wang M, Xin Z, Zhang W, Qu
J and Liu GH: Multimodal omics approaches to aging and age-related
diseases. Phenomics. 4:56–71. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hensen T and Thiele I: Metabolic modeling
links gut microbiota to metabolic markers of Parkinson's disease.
Gut Microbes. 17:25541952025. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ning L, Zhou YL, Sun H, Zhang Y, Shen C,
Wang Z, Xuan B, Zhao Y, Ma Y, Yan Y, et al: Microbiome and
metabolome features in inflammatory bowel disease via multi-omics
integration analyses across cohorts. Nat Commun. 14:71352023.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sasso JM, Ammar RM, Tenchov R, Lemmel S,
Kelber O, Grieswelle M and Zhou QA: Gut microbiome-brain alliance:
A landscape view into mental and gastrointestinal health and
disorders. ACS Chem Neurosci. 14:1717–1763. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Qian Y, Yang X, Xu S, Wu C, Song Y, Qin N,
Chen SD and Xiao Q: Alteration of the fecal microbiota in Chinese
patients with Parkinson's disease. Brain Behav Immun. 70:194–202.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Romano S, Wirbel J, Ansorge R, Schudoma C,
Ducarmon QR, Narbad A and Zeller G: Machine learning-based
meta-analysis reveals gut microbiome alterations associated with
Parkinson's disease. Nat Commun. 16:42272025. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Palmela I, Correia L, Silva RFM, Sasaki H,
Kim KS, Brites D and Brito MA: Hydrophilic bile acids protect human
blood-brain barrier endothelial cells from disruption by
unconjugated bilirubin: An in vitro study. Front Neurosci.
9:802015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Krueger ME, Boles JS, Simon ZD, Alvarez
SD, McFarland NR, Okun MS, Zimmermann EM, Forsmark CE and Tansey
MG: Comparative analysis of Parkinson's and inflammatory bowel
disease gut microbiomes reveals shared butyrate-producing bacteria
depletion. NPJ Parkinsons Dis. 11:502025. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shakoor MU, Tareen FK, Rehman Z, Saghir
KA, Ashraf W, Anjum SMM, Ahmad T, Alqahtani F and Imran I:
Probiotics by modulating gut-brain axis together with brivaracetam
mitigate seizure progression, behavioral incongruities, and
prevented neurodegeneration in pentylenetetrazole-kindled mice. CNS
Neurosci Ther. 30:e700782024. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhang L, Wei J, Liu X, Li D, Pang X, Chen
F, Cao H and Lei P: Gut microbiota-astrocyte axis: New insights
into age-related cognitive decline. Neural Regen Res. 20:990–1008.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Quinn-Bohmann N, Wilmanski T, Sarmiento
KR, Levy L, Lampe JW, Gurry T, Rappaport N, Ostrem EM, Venturelli
OS, Diener C and Gibbons SM: Microbial community-scale metabolic
modelling predicts personalized short-chain fatty acid production
profiles in the human gut. Nat Microbiol. 9:1700–1712. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Fock E and Parnova R: Mechanisms of
blood-brain barrier protection by microbiota-derived short-chain
fatty acids. Cells. 12:6572023. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ravi A, Umapathy S and Pan I: Short-chain
fatty acids as a therapeutic strategy in Parkinson's disease:
Implications for neurodegeneration. Cell Mol Neurobiol. 45:902025.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhang Y, Liu Y, Liang X, Wen Y, Zhao J, He
Y, Xie Q and Xie C: Intestinal barrier in chronic gut and liver
diseases: Pathogenesis and therapeutic targets. Acta Pharm Sin B.
15:5515–5536. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Pellegrini C, Fornai M, D'Antongiovanni V,
Antonioli L, Bernardini N and Derkinderen P: The intestinal barrier
in disorders of the central nervous system. Lancet Gastroenterol
Hepatol. 8:66–80. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Sun N, Liu W, Li J, Zhang D, Liu X, Liu J
and Hu H: Composition, function, and detection methods of the
intestinal barrier. J Nutr Biochem. 149:1101792026. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Li Y, Pan J, Liu H and Liu C: Intestinal
mucin glycosylation: Structural regulation, homeostasis maintenance
and disease association. Biomolecules. 15:15522025. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Breugelmans T, Oosterlinck B, Arras W,
Ceuleers H, De Man J, Hold GL, De Winter BY and Smet A: The role of
mucins in gastrointestinal barrier function during health and
disease. Lancet Gastroenterol Hepatol. 7:455–471. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Yang C, Lan X, Zhong H, Geng J and Wang W:
Enteric nervous system in microbiota-associated gut inflammation.
Front Immunol. 17:17357272026. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Wasiak J and Gawlik-Kotelnicka O:
Intestinal permeability and its significance in psychiatric
disorders-A narrative review and future perspectives. Behav Brain
Res. 448:1144592023. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Kalyan M, Tousif AH, Sonali S, Vichitra C,
Sunanda T, Praveenraj SS, Ray B, Gorantla VR, Rungratanawanich W,
Mahalakshmi AM, et al: Role of endogenous lipopolysaccharides in
neurological disorders. Cells. 11:40382022. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Kearns R: Gut-brain axis and
neuroinflammation: The role of gut permeability and the kynurenine
pathway in neurological disorders. Cell Mol Neurobiol. 44:642024.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Azimzadeh M, Ababzadeh S, Kahaki AG,
Babaei SMH, Seyedebrahimi R and Farsani ME: The gut-brain axis in
neurodegeneration: Mechanistic links between dysbiosis and
neuropathology. Iran J Pathol. 21:507–522. 2026.PubMed/NCBI
|
|
65
|
Fang X, Liu S, Muhammad B, Zheng M, Ge X,
Xu Y, Kan S, Zhang Y, Yu Y, Zheng K, et al: Gut microbiota
dysbiosis contributes to α-synuclein-related pathology associated
with C/EBPβ/AEP signaling activation in a mouse model of
Parkinson's disease. Neural Regen Res. 19:2081–2088. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Liang Y, Zhao Y, Fasano A and Su CW: Gut
permeability and microbiota in Parkinson's disease: Mechanistic
insights and experimental therapeutic strategies. Int J Mol Sci.
26:95932025. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Mimori S, Kawada K, Saito R, Takahashi M,
Mizoi K, Okuma Y, Hosokawa M and Kanzaki T: Indole-3-propionic acid
has chemical chaperone activity and suppresses endoplasmic
reticulum stress-induced neuronal cell death. Biochem Biophys Res
Commun. 517:623–628. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Meng S: The role of indole metabolites
derived from gut microbiota in Parkinson's disease: A comprehensive
review. Brain Res Bull. 237:1117752026. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Chen M and Mor DE: Gut-to-brain
α-synuclein transmission in Parkinson's disease: Evidence for
prion-like mechanisms. Int J Mol Sci. 24:72052023. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Nordengen K and Morland C: From synaptic
physiology to synaptic pathology: The enigma of α-synuclein. Int J
Mol Sci. 25:9862024. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Pitton Rissardo J, McGarry A, Shi Y,
Fornari Caprara AL and Kannarkat GT: Alpha-synuclein neurobiology
in Parkinson's disease: A comprehensive review of its role,
mechanisms, and therapeutic perspectives. Brain Sci. 15:12602025.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Sharma M and Burré J: α-Synuclein in
synaptic function and dysfunction. Trends Neurosci. 46:153–166.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Shamoto-Nagai M, Hisaka S, Naoi M and
Maruyama W: Modification of α-synuclein by lipid peroxidation
products derived from polyunsaturated fatty acids promotes toxic
oligomerization: Its relevance to Parkinson disease. J Clin Biochem
Nutr. 62:207–212. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Erny D and Prinz M: Microbiology: Gut
microbes augment neurodegeneration. Nature. 544:304–305. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Kalyanaraman B, Cheng G and Hardy G: Gut
microbiome, short-chain fatty acids, alpha-synuclein,
neuroinflammation, and ROS/RNS: Relevance to Parkinson's disease
and therapeutic implications. Redox Biol. 71:1030922024. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Shin C, Ruhno KE, Shin JH, Hwang S, Go JR,
Kang M and Kim HJ, Moon JH and Kim HJ: Spatial transcriptome
analysis of myenteric plexus and intestinal epithelium of colon in
patients with Parkinson's disease. Acta Neuropathol Commun.
13:1462025. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Balsamo JM, Yan Y, Thai D, Cologna SM and
Bess EN: Multiomic analysis reveals molecular pathways associated
with intestinal aggregation of α-synuclein. bioRxiv [Preprint].
2025.08.27.672706. 2025.
|
|
78
|
Lau K, Kotzur R and Richter F: Blood-brain
barrier alterations and their impact on Parkinson's disease
pathogenesis and therapy. Transl Neurodegener. 13:372024.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Höglinger GU, Adler CH, Berg D, Klein C,
Outeiro TF, Poewe W, Postuma R, Stoessl AJ and Lang AE: A
biological classification of Parkinson's disease: The SynNeurGe
research diagnostic criteria. Lancet Neurol. 23:191–204. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Rissardo JP and Fornari Caprara AL:
Alpha-synuclein seed amplification assays in Parkinson's disease: A
systematic review and network meta-analysis. Clin Pract.
15:1072025. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Dasari M and Medapati RV: Cerebrospinal
fluid biomarkers for diagnosis of Parkinson's disease: A systematic
review. Cureus. 17:e793862025.PubMed/NCBI
|
|
82
|
McWilliam OH, Bsoul R, Lund EL, Waldemar
G, Hasselbalch SG, Simonsen AH, Bruun M, von Buchwald C, Aanæs K,
Pedersen CK, et al: α-Synuclein seed amplification assay in Lewy
body dementia versus Alzheimer's disease. Alzheimers Dement (Amst).
17:e702032025. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Giannakis A, Pechlivani L, Sioka C,
Alexiou G, Konitsiotis S and Kyritsis AP: Seed amplification assay
for α-synuclein: Diagnostic applications in synucleinopathies. Int
J Mol Sci. 26:78172025. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Concha-Marambio L, Pritzkow S, Shahnawaz
M, Farris CM and Soto C: Seed amplification assay for the detection
of pathologic alpha-synuclein aggregates in cerebrospinal fluid.
Nat Protoc. 18:1179–1196. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Orrú CD, Vaughan DP, Vijiaratnam N, Real
R, Martinez-Carrasco A, Fumi R, Jensen MT, Hodgson M, Girges C,
Gil-Martinez AL, et al: Diagnostic and prognostic value of
α-synuclein seed amplification assay kinetic measures in
Parkinson's disease: A longitudinal cohort study. Lancet Neurol.
24:580–590. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Yoo D, Bang JI, Ahn C, Nyaga VN, Kim YE,
Kang MJ and Ahn TB: Diagnostic value of α-synuclein seeding
amplification assays in α-synucleinopathies: A systematic review
and meta-analysis. Parkinsonism Relat Disord. 104:99–109. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Hampel H, Goetzl EJ, Kapogiannis D, Lista
S and Vergallo A: Biomarker-drug and liquid biopsy co-development
for disease staging and targeted therapy: Cornerstones for
Alzheimer's precision medicine and pharmacology. Front Pharmacol.
10:3102019. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Schulz I, Kruse N, Gera RG, Kremer T,
Cedarbaum J, Barbour R, Zago W, Schade S, Otte B, Bartl M, et al:
Systematic assessment of 10 biomarker candidates focusing on
α-synuclein-related disorders. Mov Disord. 36:2874–2887. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Liu TW, Chen CM and Chang KH: Biomarker of
neuroinflammation in Parkinson's disease. Int J Mol Sci.
23:41482022. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Liu X, Liu Y, Liu J, Zhang H, Shan C, Guo
Y, Gong X, Cui M, Li X and Tang M: Correlation between the gut
microbiome and neurodegenerative diseases: A review of metagenomics
evidence. Neural Regen Res. 19:833–845. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Qian Y, Yang X, Xu S, Huang P, Li B, Du J,
He Y, Su B, Xu LM, Wang L, et al: Gut metagenomics-derived genes as
potential biomarkers of Parkinson's disease. Brain. 143:2474–2489.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Maggi G, Vitale C, Cerciello F and
Santangelo G: Sleep and wakefulness disturbances in Parkinson's
disease: A meta-analysis on the prevalence and clinical aspects of
REM sleep behaviour disorder, excessive daytime sleepiness and
insomnia. Sleep Med Rev. 68:1017592023. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Iranzo A, Cochen De Cock V, Fantini ML,
Pérez-Carbonell L and Trotti LM: Sleep and sleep disorders in
people with Parkinson's disease. Lancet Neurol. 23:925–937. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Cardenas-Saenz O, Macias-Ortiz FG,
Becerra-Aguiar NN, Sainz-Del Real SMLA, Orozco-Puga P,
Camacho-Ordoñez A and Rodriguez-Violante MJ: Unraveling the link
between sleep disturbances and Parkinson's disease: A narrative
review. Acta Neurol Taiwan. 34:196–209. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Yalçin M, Grande V, Outeiro TF and Relógio
A: Circadian clock dysfunction in Parkinson's disease: Mechanisms,
consequences, and therapeutic strategy. NPJ Parkinsons Dis.
11:2132025. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Neilson LE, Khattab YI and Lim MM: REM
Sleep behavior disorder as a prodromal synucleinopathy: Updates on
clinical and laboratory biomarkers, and implications for
neuroprotective trials. Curr Neurol Neurosci Rep. 25:732025.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Yoon EJ and Monchi O: Probable REM sleep
behavior disorder is associated with longitudinal cortical thinning
in Parkinson's disease. NPJ Parkinsons Dis. 7:192021. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Al-qahtani Z, Alasmre LAA, Alasmre HAA,
Alshahrani AA, Ghabrah RM, Alhebshi RAA and Garah BMB: The impact
of sleep disorders on nonmotor symptoms in patients with
Parkinson's disease; a systematic review. Int J Med Dev.
9:2919–2926. 2025.
|
|
99
|
Doppler K, Mammadova S, Kuzkina A, Reetz
K, Michels J, Hermann W, Sommerauer M, Volkmann J, Oertel WH,
Janzen A and Sommer C: Association between probable REM sleep
behavior disorder and increased dermal alpha-synuclein deposition
in Parkinson's disease. Parkinsonism Relat Disord. 99:58–61. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Anderson KN, Keogh MJ and Gosse L: Sleep
disturbance in Parkinson's disease: Consequences for the brain and
disease progression-A narrative review. Nat Sci Sleep.
17:1521–1537. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Stefani A, Antelmi E, Arnaldi D, Arnulf I,
During E, Högl B, Hu MMT, Iranzo A, Luke R, Peever J, et al: From
mechanisms to future therapy: A synopsis of isolated REM sleep
behavior disorder as early synuclein-related disease. Mol
Neurodegener. 20:192025. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
McFarthing K, Buff S, Rafaloff G, Pitzer
K, Fiske B, Navangul A, Beissert K, Pilcicka A, Fuest R, Wyse RK
and Stott SRW: Parkinson's disease drug therapies in the clinical
trial pipeline: 2024 update. J Parkinsons Dis. 14:899–912. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Marsili L, Bologna M, Chen LY and Espay
AJ: Treatment of motor symptoms of Parkinson's disease. Neurol
Clin. 43:341–363. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Langeskov-Christensen M, Franzén E,
Grøndahl Hvid L and Dalgas U: Exercise as medicine in Parkinson's
disease. J Neurol Neurosurg Psychiatry. 95:1077–1088. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Festa LK, Grinspan JB and Jordan-Sciutto
KL: White matter injury across neurodegenerative disease. Trends
Neurosci. 47:47–57. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
de Bie RMA, Katzenschlager R, Swinnen
BEKS, Peball M, Lim SY, Mestre TA, Perez Lloret S, Coelho M, Aquino
C, Tan AH, et al: Update on treatments for Parkinson's disease
motor fluctuations-an international parkinson and movement disorder
society evidence-based medicine review. Mov Disord. 40:776–794.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Huang J, Gong C and Zhou A: Modulation of
gut microbiota: A novel approach to enhancing the effects of immune
checkpoint inhibitors. Ther Adv Med Oncol.
15:175883592312048542023. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Yoo S, Jung SC, Kwak K and Kim JS: The
role of prebiotics in modulating gut microbiota: Implications for
human health. Int J Mol Sci. 25:48342024. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Rau S, Gregg A, Yaceczko S and Limketkai
B: Prebiotics and probiotics for gastrointestinal disorders.
Nutrients. 16:7782024. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Deng S, Pei C, Cai K, Huang W, Xiao X,
Zhang X, Liang R, Chen Y, Xie Z, Li P and Liao Q: Lactobacillus
acidophilus and its metabolite ursodeoxycholic acid ameliorate
ulcerative colitis by promoting Treg differentiation and inhibiting
M1 macrophage polarization. Front Microbiol. 15:13029982024.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Kennedy JM, De Silva A, Walton GE and
Gibson GR: A review on the use of prebiotics in ulcerative colitis.
Trends Microbiol. 32:507–515. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Abdel-Haq R, Schlachetzki JCM, Boktor JC,
Cantu-Jungles TM, Thron T, Zhang M, Bostick JW, Khazaei T,
Chilakala S, Morais LH, et al: A prebiotic diet modulates
microglial states and motor deficits in α-synuclein overexpressing
mice. Elife. 11:e814532022. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Liu X, Du ZR, Wang X, Sun XR, Zhao Q, Zhao
F, Wong WT, Wong KH and Dong XL: Polymannuronic acid prebiotic plus
Lacticaseibacillus rhamnosus GG probiotic as a novel
synbiotic promoted their separate neuroprotection against
Parkinson's disease. Food Res Int. 155:1110672022. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Petrov VA, Schade S, Laczny CC, Hällqvist
J, May P, Jäger C, Aho VTE, Hickl O, Halder R, Lang E, et al:
Resistant starch improves Parkinson's disease symptoms through
restructuring of the gut microbiome and modulating inflammation.
Brain Behav Immun. 132:1062172026. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Perez-Pardo P, de Jong EM, Broersen LM,
van Wijk N, Attali A, Garssen J and Kraneveld AD: Promising effects
of neurorestorative diets on motor, cognitive, and gastrointestinal
dysfunction after symptom development in a mouse model of
Parkinson's disease. Front Aging Neurosci. 9:572017. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Kumar D, Bishnoi M, Kondepudi KK and
Sharma SS: Gut microbiota-based interventions for Parkinson's
disease: Neuroprotective mechanisms and current perspective.
Probiot Antimicrob Proteins. 17:2438–2460. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Panaitescu PȘ, Răzniceanu V,
Mocrei-Rebrean ȘM, Neculicioiu VS, Dragoș HM, Costache C and Filip
GA: The effect of gut microbiota-targeted interventions on
neuroinflammation and motor function in Parkinson's disease animal
models-a systematic review. Curr Issues Mol Biol. 46:3946–3974.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Poluektova EU, Stavrovskaya A, Pavlova A,
Yunes R, Marsova M, Koshenko T, Illarioshkin S and Danilenko V: Gut
microbiome as a source of probiotic drugs for Parkinson's disease.
Int J Mol Sci. 26:92902025. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Kim N, Yun M, Oh YJ and Choi HJ:
Mind-altering with the gut: Modulation of the gut-brain axis with
probiotics. J Microbiol. 56:172–182. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Zuo S, Wang H, Zhao Q, Tang J, Wang M,
Zhang Y, Sang M, Tian J and Wang P: High levels of
Bifidobacteriaceae are associated with the pathogenesis of
Parkinson's disease. Front Integr Neurosci. 16:10546272022.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Anderson RC: Can probiotics mitigate
age-related neuroinflammation leading to improved cognitive
outcomes? Front Nutr. 9:10120762022. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Liu Q, Yu Z, Tian F, Zhao J, Zhang H, Zhai
Q and Chen W: Surface components and metabolites of probiotics for
regulation of intestinal epithelial barrier. Microb Cell Fact.
19:232020. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Moiseyenko A, Antonello G, Schonhoff AM,
Boktor JC, Long K, Dirks B, Oguienko AD, Winnett AV, Simpson P,
Daeizadeh D, et al: Faecalibacterium prausnitzii, depleted
in the Parkinson's disease microbiome, improves motor deficits in
α-synuclein overexpressing mice. NPJ Parkinsons Dis. 12:942026.
View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Hsieh TH, Kuo CW, Hsieh KH, Shieh MJ, Peng
CW, Chen YC, Chang YL, Huang YZ, Chen CC, Chang PK, et al:
Probiotics alleviate the progressive deterioration of motor
functions in a mouse model of Parkinson's disease. Brain Sci.
10:2062020. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Zhao X, Zhou J, Liang W, Sheng Q, Lu L,
Chen T, Chen J, Tan K and Lv Z: Probiotics mixture reinforces
barrier function to ameliorate necrotizing enterocolitis by
regulating PXR-JNK pathway. Cell Biosci. 11:202021. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Yang L, Guo T, Wei Y, Zhang Z, Sun Y, Yan
N, Ding S, Jiang L and Liu H: Lactobacillus acidophilus
exerts neuroprotective effects in MPTP mice: Potential links to the
gut microbiota and GLP-1. Physiol Behav. 307:1152292026. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Lin M, Li S, Lin J, Wan J, Xu T, Qi X, Wei
J, Li J, Chen T and Tu H: The adjunct use of Bifidobacterium
animalis subsp. lactis BAMA-B06/BAu-B0111 improves the therapeutic
efficacy of Liuwei'anxiao Capsule in alleviating constipation in
Parkinson's Disease: A randomized controlled study. J
Ethnopharmacol. 367:1216942026. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Du Y, Wang L, Cui Y, Xu X, Zhang M, Li Y,
Gao T, Gao D, Sheng Z, Wang S and Tuo H: Effect of probiotics
supplementation on REM sleep behavior disorder and motor symptoms
in Parkinson's disease: A pilot study. CNS Neurosci Ther.
31:e705412025. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
van Kessel SP and El Aidy S: Contributions
of gut bacteria and diet to drug pharmacokinetics in the treatment
of Parkinson's disease. Front Neurol. 10:10872019. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Marx W, Suo C, Dissanayaka T, Maleki S,
Nguyen L, Travica N, Mohebbi M, Lotfaliany M, Yucel M, McGuinness
AJ, et al: Effects of a probiotic fermented dairy product on
hippocampal metabolites, structure and function: An 8-week
randomised, placebo-controlled trial in healthy women. Gut.
75:511–520. 2025. View Article : Google Scholar
|
|
131
|
Luo Y, Li Z, Gu L and Zhang K: Fermented
dairy foods consumption and depressive symptoms: A meta-analysis of
cohort studies. PLoS One. 18:e02813462023. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Danika A and Supital AP: The role of
probiotics in improving motor function in Parkinson's disease:
Evidence from a systematic review and meta-analysis. Int J Med Sci
Health Res. 16:1–19. 2025. View Article : Google Scholar
|
|
133
|
Priya M and de Carvalho LPS:
Circumnavigating antibiotic mechanisms of action and resistance
research. Biochemistry. 65:249–262. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Chinnathambi S, Rangappa N and Malik S:
Antimicrobial peptides inhibit Tau aggregation and modulates its
pathology. Adv Protein Chem Struct Biol. 149:375–394. 2026.
View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Behera P, Rangappa N, Chandrashekar M,
Mishra A, Chinnathambi S and Mishra M: The multifaceted role of
antimicrobial peptides in neurodegeneration: Insights from
Drosophila and beyond. Adv Protein Chem Struct Biol. 149:419–444.
2026. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Wei J, Liu C, Qin D, Ren F, Duan J, Chen T
and Wu A: Targeting inflammation and gut microbiota with
antibacterial therapy: Implications for central nervous system
health. Ageing Res Rev. 102:1025442024. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Sorboni SG, Moghaddam HS,
Jafarzadeh-Esfehani R and Soleimanpour S: A comprehensive review on
the role of the gut microbiome in human neurological disorders.
Clin Microbiol Rev. 35:e00338202022. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Teng M, Ma R, Liu S, Zhang G, Zou J and Fu
Q: Bacterial infection hypothesis-based therapies for Alzheimer's
disease. Chem Eng J. 524:1695352025. View Article : Google Scholar
|
|
139
|
Nuzum ND, Szymlek-Gay EA, Loke S, Dawson
SL, Teo WP, Hendy AM, Loughman A and Macpherson H: Differences in
the gut microbiome across typical ageing and in Parkinson's
disease. Neuropharmacology. 235:1095662023. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Zhang Y, Mo C, He X, Xiao Q and Yang X:
Gut microbial community of patients with Parkinson's disease
analyzed using metagenome-assembled genomes. Neural Regen Res.
21:3815–3823. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Ruzza P, Siligardi G, Hussain R, Marchiani
A, Islami M, Bubacco L, Delogu G, Fabbri D, Dettori MA, Sechi M, et
al: Ceftriaxone blocks the polymerization of α-synuclein and exerts
neuroprotective effects in vitro. ACS Chem Neurosci. 5:30–38. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Teran MDM, Tomas-Grau RH, Soliz-Santander
ES, Guayán ML, Budeguer Isa V, Luna Mercado A, Avila CL,
Sosa-Padilla B, Cruz H, Ciss I, et al: DDOX expands the repertoire
of tetracyclines for Parkinson's disease by preventing the cellular
uptake and intracellular impact of α-synuclein preformed fibrils.
Sci Rep. 15:377692025. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Fu M, Wang Q, Gao L, Yuan X and Wang J:
Antimicrobial drugs for Parkinson's disease: Existing therapeutic
strategies and novel drugs exploration. Ageing Res Rev.
99:1023872024. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Wu J, Li CS, Huang WY, Zhou SY, Zhao LP,
Li T, Li MA, Zhang MX, Qiao CM, Zhao WJ, et al: Gut microbiota
promote the propagation of pathologic α-syn from gut to brain in a
gut-originated mouse model of Parkinson's disease. Brain Behav
Immun. 128:152–169. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Shi X, Sun Y, Hosseini S, Chen F, Cordes
T, Michaelsen-Preusse K and Korte M: Ceftriaxone attenuates Poly
I:C-induced neuroinflammation in vitro by modulating glutamate
transport, synaptic integrity, and immunometabolic reprogramming.
Front Cell Neurosci. 19:16843982025. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Zhi H, Wang X, Chen Y, Cai Z, Li J and Guo
D: Ceftriaxone affects ferroptosis and alleviates glial cell
activation in Parkinson's disease. Int J Mol Med. 55:852025.
View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Hakimizadeh E, Kaeidi A, Taghipour Z,
Mehrzadi S, Allahtavakoli M, Shamsizadeh A, Bazmandegan G,
Hassanshahi J, Aflatoonian MR and Fatemi I: Ceftriaxone improves
senile neurocognition damages induced by D-galactose in mice. Iran
J Basic Med Sci. 23:368–375. 2020.PubMed/NCBI
|
|
148
|
Zong T, Li N, Han F, Liu J, Deng M, Li V,
Zhang M, Zhou Y and Yu M: Microglial depletion rescues spatial
memory impairment caused by LPS administration in adult mice.
PeerJ. 12:e185522024. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Kraus RL, Pasieczny R, Lariosa-Willingham
K, Turner MS, Jiang A and Trauger JW: Antioxidant properties of
minocycline: Neuroprotection in an oxidative stress assay and
direct radical-scavenging activity. J Neurochem. 94:819–827. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Cheng G, Liu Z, Yan Z, Wu J, Li Z, Gao S,
Zheng C, Guo S, Pan Y, Chen X, et al: Minocycline nanoplatform
penetrates the BBB and enables the targeted treatment of
Parkinson's disease with cognitive impairment. J Control Release.
377:591–605. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Balducci C and Forloni G: Doxycycline for
Alzheimer's disease: Fighting β-amyloid oligomers and
neuroinflammation. Front Pharmacol. 10:7382019. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Ali NH, Al-Kuraishy HM, Hussain NR,
Al-Gareeb AI, Albuhadily AK, Waheeb TS and Batiha GES: Repurposing
of doxycycline as a novel therapeutic avenue for management of
Parkinson's disease. Inflammopharmacology. 34:3193–3207. 2026.
View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Cui C, Hong H, Shi Y, Zhou Y, Qiao CM,
Zhao WJ, Zhao LP, Wu J, Quan W, Niu GY, et al: Vancomycin
pretreatment on MPTP-induced Parkinson's disease mice exerts
neuroprotection by suppressing inflammation both in brain and gut.
J Neuroimmune Pharmacol. 18:72–89. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Bi W, Zhu L, Jing X, Zeng Z, Liang Y, Xu
A, Liu J, Xiao S, Yang L, Shi Q, et al: Rifampicin improves
neuronal apoptosis in LPS-stimulated co-cultured BV2 cells through
inhibition of the TLR-4 pathway. Mol Med Rep. 10:1793–1799. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Sahoo SS, Paidesetty SK, Sahu PK,
Pattanaik S and Dandela R: Therapeutic innovation through drug
repurposing: A multidimensional approach toward treating
Parkinson's disease. Bioorg Chem. 166:1091292025. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Singh Y, Trautwein C, Romani J, Salker MS,
Neckel PH, Fraccaroli I, Abeditashi M, Woerner N, Admard J,
Dhariwal A, et al: Overexpression of human alpha-synuclein leads to
dysregulated microbiome/metabolites with ageing in a rat model of
Parkinson disease. Mol Neurodegener. 18:442023. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Halawa EM, Fadel M, Al-Rabia MW, Behairy
A, Nouh NA, Abdo M, Olga R, Fericean L, Atwa AM, El-Nablaway M and
Abdeen A: Antibiotic action and resistance: Updated review of
mechanisms, spread, influencing factors, and alternative approaches
for combating resistance. Front Pharmacol. 14:13052942024.
View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Duan H, Yu L, Tian F, Zhai Q, Fan L and
Chen W: Antibiotic-induced gut dysbiosis and barrier disruption and
the potential protective strategies. Crit Rev Food Sci Nutr.
62:1427–1452. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Green JE, Wrobel A, Todd E, Marx W, Berk
M, Lotfaliany M, Castle D, Cryan JF, Athan E, Hair C, et al: Early
antibiotic exposure and risk of psychiatric and neurocognitive
outcomes: Systematic review and meta-analysis. Br J Psychiatry.
226:171–183. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Socała K, Doboszewska U, Szopa A, Serefko
A, Włodarczyk M, Zielińska A, Poleszak E, Fichna J and Wlaź P: The
role of microbiota-gut-brain axis in neuropsychiatric and
neurological disorders. Pharmacol Res. 172:1058402021. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Hegelmaier T, Lebbing M, Duscha A, Tomaske
L, Tönges L, Holm JB, Bjørn Nielsen H, Gatermann SG, Przuntek H and
Haghikia A: Interventional influence of the intestinal microbiome
through dietary intervention and bowel cleansing might improve
motor symptoms in Parkinson's disease. Cells. 9:3762020. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Leta V, Klingelhoefer L, Longardner K,
Campagnolo M, Levent HÇ, Aureli F, Metta V, Bhidayasiri R,
Chung-Faye G, Falup-Pecurariu C, et al: Gastrointestinal barriers
to levodopa transport and absorption in Parkinson's disease. Eur J
Neurol. 30:1465–1480. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Caccia C: Pharmaco-EEG and brain mapping:
Theory, applications and validation. J Psychopharmacol. 12:8–16.
2014.
|
|
164
|
Dinan K and Dinan T: Antibiotics and
mental health: The good, the bad and the ugly. J Intern Med.
292:858–869. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Olanow CW, Obeso JA and Stocchi F:
Continuous dopamine-receptor treatment of Parkinson's disease:
Scientific rationale and clinical implications. Lancet Neurol.
5:677–687. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Kakarla R, Karuturi P, Siakabinga Q, Kasi
Viswanath M, Dumala N, Guntupalli C, Nalluri BN, Venkateswarlu K,
Prasanna VS, Gutti G, et al: Current understanding and future
directions of cruciferous vegetables and their phytochemicals to
combat neurological diseases. Phytother Res. 38:1381–1399. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Bessetti RN and Litwa KA: Broccoli for the
brain: A review of the neuroprotective mechanisms of sulforaphane.
Front Cell Neurosci. 19:16013662025. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Saito A, Ishikawa S, Yang K, Sawa A and
Ishizuka K: Sulforaphane as a potential therapeutic agent: A
comprehensive analysis of clinical trials and mechanistic insights.
J Nutr Sci. 14:e652025. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Mohamad KA, El-Naga RN and Wahdan SA:
Neuroprotective effects of indole-3-carbinol on the rotenone rat
model of Parkinson's disease: Impact of the SIRT1-AMPK signaling
pathway. Toxicol Appl Pharmacol. 435:1158532022. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Kurowska A, Ziemichód W, Herbet M and
Piątkowska-Chmiel I: The role of diet as a modulator of the
inflammatory process in the neurological diseases. Nutrients.
15:14362023. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Hegelmaier T, Duscha A, Desel C, Fuchs S,
Shapira M, Amidror S, Shan Q, Stangl GI, Hirche F, Kempa S, et al:
Supplementation with short-chain fatty acids and a prebiotic
improves clinical outcome in Parkinson's disease: A randomized
double-blind prospective study. Sci Rep. 16:3152025. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Koch S, Laabs BH, Kasten M, Vollstedt EJ,
Becktepe J, Brüggemann N, Franke A, Krämer UM, Kuhlenbäumer G, Lieb
W, et al: Validity and prognostic value of a polygenic risk score
for Parkinson's disease. Genes (Basel). 12:18592021. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Shokri-Mashhadi N, Ghiasvand R, Feizi A,
Ebrahimi-Monfared M, Vahid F and Banijamali A: Association between
major dietary patterns and Parkinson's disease risk: A case-control
study. Neurol Sci. 45:2003–2010. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Sharma R, Bhate L, Agrawal Y and Aspatwar
A: Advanced nutraceutical approaches to Parkinson's disease:
Bridging nutrition and neuroprotection. Nutr Neurosci.
28:1134–1150. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Zhang F, Cui B, He X, Nie Y, Wu K and Fan
D; FMT-standardisation Study Group, : Microbiota transplantation:
Concept, methodology and strategy for its modernization. Protein
Cell. 9:462–473. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Nabil Y, Helal MM, Qutob IA, Dawoud AIA,
Allam S, Haddad R, Manasrah GM, AlEdani EM, Sleibi W, Faris A, et
al: Efficacy and safety of fecal microbiota transplantation in the
management of parkinson's disease: A systematic review. BMC Neurol.
25:2912025. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Chen K, Sun L, Liu Y and Chen R: Safety
and efficacy of fecal microbiota transplantation in the treatment
of Parkinson's disease: A systematic review of clinical trials.
Front Neurosci. 19:16399112025. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Yang D, Zhao D, Ali Shah SZ, Wu W, Lai M,
Zhang X, Li J, Guan Z, Zhao H, Li W, et al: The role of the gut
microbiota in the pathogenesis of Parkinson's disease. Front
Neurol. 10:11552019. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Zhang T, Wang T, Chen X, Zhao Z and Chen
Z: Gut microbiota relieves inflammation in the substantia nigra of
chronic Parkinson's disease by protecting the function of dopamine
neurons. Exp Ther Med. 23:522022. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Sun MF, Zhu YL, Zhou ZL, Jia XB, Xu YD,
Yang Q, Cui C and Shen YQ: Neuroprotective effects of fecal
microbiota transplantation on MPTP-induced Parkinson's disease
mice: Gut microbiota, glial reaction and TLR4/TNF-α signaling
pathway. Brain Behav Immun. 70:48–60. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Sampson TR, Debelius JW, Thron T, Janssen
S, Shastri GG, Ilhan ZE, Challis C, Schretter CE, Rocha S,
Gradinaru V, et al: Gut microbiota regulate motor deficits and
neuroinflammation in a model of Parkinson's disease. Cell.
167:1469–1480.e12. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Cheng Y, Tan G, Zhu Q, Wang C, Ruan G,
Ying S, Qie J, Hu X, Xiao Z, Xu F, et al: Efficacy of fecal
microbiota transplantation in patients with Parkinson's disease:
Clinical trial results from a randomized, placebo-controlled
design. Gut Microbes. 15:22842472023. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Scheperjans F, Levo R, Bosch B, Lääperi M,
Pereira PAB, Smolander OP, Aho VTE, Vetkas N, Toivio L, Kainulainen
V, et al: Fecal microbiota transplantation for treatment of
Parkinson disease: A randomized clinical Trial. JAMA Neurol.
81:925–938. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Beckers M, Coburn B, Kalia LV and Bloem
BR: A randomized controlled trial of fecal microbiota
transplantation for Parkinson's disease: Getting it right, if not
PARFECT. J Parkinsons Dis. 14:913–915. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Wang J, Xue L, Zhang M, Shen P, Zhao W,
Tong Q, Wu S, Dai W, Yang X and Wang H: Colonoscopic fecal
microbiota transplantation for mild-to-moderate Parkinson's
disease: A randomized controlled trial. Brain Behav Immun.
130:1060862025. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Guo B, Zhang M, Hao W, Wang Y, Zhang T and
Liu C: Neuroinflammation mechanisms of neuromodulation therapies
for anxiety and depression. Transl Psychiatry. 13:52023. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Yap JYY, Keatch C, Lambert E, Woods W,
Stoddart PR and Kameneva T: Critical review of transcutaneous vagus
nerve stimulation: Challenges for translation to clinical practice.
Front Neurosci. 14:2842020. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Butt MF, Albusoda A, Farmer AD and Aziz Q:
The anatomical basis for transcutaneous auricular vagus nerve
stimulation. J Anat. 236:588–611. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Gouveia FV, Warsi NM, Suresh H, Matin R
and Ibrahim GM: Neurostimulation treatments for epilepsy: Deep
brain stimulation, responsive neurostimulation and vagus nerve
stimulation. Neurotherapeutics. 21:e003082024. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Svensson E, Horváth-Puhó E, Thomsen RW,
Djurhuus JC, Pedersen L, Borghammer P and Sørensen HT: Vagotomy and
subsequent risk of Parkinson's disease. Ann Neurol. 78:522–529.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Yang Z, Wang Y, Wei M, Li S, Jia C, Cheng
C, Al-Nusaif M, Zhang J, Liu C and Le W: Intrastriatal injection of
Parkinson's disease intestine and vagus lysates initiates
α-synucleinopathy in rat brain. Cell Death Dis. 14:42023.
View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Huang L, Hu B, Zhang Z, Sun Y, Huang J,
Zhang C, Zhou W and Tu H: Cervical vagus nerve as a checkpoint to
block the gut-brain transmission of α-synuclein for early
Parkinson's disease. Chem Eng J. 516:1640312025. View Article : Google Scholar
|
|
193
|
Li ZH, Yang WM, Huang Q, Shi GX, Liu CZ
and Zhang YQ: Acupuncture activates vagus nerve-macrophage axis and
improves cardiac electrophysiology and inflammatory response in
rats with atrial fibrillation via α7nAChR-JAK2/STAT3 pathway. J
Integr Med. 23:398–414. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Shan J, Li Z, Ji M, Zhang M, Zhang C, Zhu
Y and Feng Z: Transcutaneous vagus nerve stimulation for
Parkinson's disease: A systematic review and meta-analysis. Front
Aging Neurosci. 16:14981762025. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Pitton Rissardo J and Fornari Caprara AL:
Transcutaneous vagus nerve stimulation for gait and motor function
in Parkinson's disease: A systematic review and meta-analysis of
randomized controlled trials. Mov Disord. 40 (Suppl
1):S5192025.
|
|
196
|
Sigurdsson HP, Hunter H, Alcock L, Maughan
EE, Bramley H, Brown P, Palermo G, Baker MR, Taylor JP, Rochester L
and Yarnall AJ: Feasibility, safety and efficacy of multi-dose
vagus nerve stimulation in Parkinson's disease: A double-blind,
randomised sham-controlled proof-of-concept study. J Neurol.
272:6842025. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Proietti F, Ottaviani MM, Burchi E,
Vivacqua G, Anzini G, Ricciuti RA, Capone F, Macefield VG, Di
Lazzaro V and Marano M: Vagus nerve stimulation in movement
disorders, from principles to a systematic review of evidence. Mov
Disord. 40:2559–2577. 2025. View Article : Google Scholar : PubMed/NCBI
|
